BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| Lycium barbarum x Lycium chinense, {Goji Fruit, Juice} - Akkermansia muciniphila ATCC BAA-835 |
👶
The polysaccharides from the fruits of Lycium barbarum L. modify the gut community profile and alleviate dextran sulfate sodium-induced colitis in mice. International journal of biological macromolecules (Int J Biol Macromol ) Vol: 222 Issue Pt B Pages: 2244-2257 Pub: 2022 Dec 1 Epub: 2022 Oct 8 Authors Zhou W , Kan X , Chen G , Sun Y , Ran L , Yan Y , Mi J , Lu L , Zeng X , Cao Y , Publication |
| Lycium barbarum x Lycium chinense, {Goji Fruit, Juice} - Akkermansia muciniphila ATCC BAA-835 |
👶
Lycium barbarum L. Balanced intestinal flora with YAP1/FXR activation in drug-induced liver injury. International immunopharmacology (Int Immunopharmacol ) Vol: 130 Issue Pages: 111762 Pub: 2024 Mar 30 Epub: 2024 Feb 29 Authors Lu J , Gao Y , Gong Y , Yue Y , Yang Y , Xiong Y , Zhang Y , Xiao Y , Wang H , Fan H , Shi X , Publication |
| Lycium barbarum x Lycium chinense, {Goji Fruit, Juice} - Akkermansia muciniphila ATCC BAA-835 |
👶
Wolfberry, Yam, and Chrysanthemum polysaccharides increased intestinal Akkermansia muciniphila abundance and hepatic YAP1 expression to alleviate DILI. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J ) Vol: 37 Issue 12 Pages: e23286 Pub: 2023 Dec Epub: Authors Lu J , Gong Y , Gao Y , Yang Y , Zhang Y , Zhang Z , Shi X , Publication |
| Lycium barbarum x Lycium chinense, {Goji Fruit, Juice} - Akkermansia muciniphila ATCC BAA-835 |
👶
Wolfberry enhanced the abundance of Akkermansia muciniphila by YAP1 in mice with acetaminophen-induced liver injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J ) Vol: 37 Issue 1 Pages: e22689 Pub: 2023 Jan Epub: Authors Liu Y , Xue Y , Zhang Z , Ji J , Li C , Zheng K , Lu J , Gao Y , Gong Y , Zhang Y , Shi X , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
